SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.74+1.0%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (256)2/21/2019 11:31:21 PM
From: scaram(o)uche   of 294
 
The first two authors contributed equally to the work. Second author is from Irv's realm, and the conclusions/vision might be forced into a FTSV slant.........

"The current results suggest that, while activating macrophage antitumor phagocytosis, CD47 blockade might also inhibit CD8+ T cell antitumor activity. However, such inhibition might be overcome using PD-1 blockade, a cancer immunotherapy currently thought to function primarily via CD8+ T cell activation. Interestingly, it was recently shown that, similar to tumor-infiltrating T cells, tumor-associated macrophages also express PD-1 co-inhibitory receptors 73. Thus cancer therapies targeting PD-1 or its ligand could be activating macrophage functions as well as T cells. A combination of PD-1 and CD47 blockade could have synergistic effects by potentiating the antitumor activity by both macrophages and T cells."

Translation...... TRIL must be perfectly situated, abscopal immunity will pop up everywhere, and all cancers on Earth will be cured. Tomorrow!

Conclusion....... the share price would be $1,000/share, if not for the Nic/Parsons act. And I have some land in Florida that you must consider!

(Thanks for the pointer! Interesting work.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext